
ELIE ISHAG TO RETIRE FROM CLINUVEL BOARD

Melbourne, Australia, 4 October 2017

CLINUVEL PHARMACEUTICALS LTD [ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION: CLVLY; XETRA-DAX: UR9] today announced that Mr Elie Ishag has advised that he will not stand for re-election as Non-Executive Director of CLINUVEL at the Company's 2017 Annual General Meeting. He will continue to serve on the Board of CLINUVEL until the date of the Meeting.

Mr Ishag has been a shareholder of the Company for 12 years and has served on the Board of Directors since February 2011. He has been a member of the Remuneration Committee since 2014 and a member of the Nomination Committee since 2016.

"I would like to thank Elie for his important contribution to CLINUVEL over the past six and a half years," CLINUVEL's Chair, Mr Stan McLiesh said. "When Elie first joined CLINUVEL, the Company's core focus was the clinical development of an innovative first-in-class drug in a rare disease with an unmet clinical need. During his time on the Board, CLINUVEL navigated through an enormously challenging regulatory process which has culminated in a marketing authorisation and a successful product launch in a major market.

"Elie leaves CLINUVEL after it recently reported a first-time profit, with positive cash flow, and in a position where it is well placed to take opportunities to expand into new markets. Elie's insight and drive has been a positive influence on the Company throughout this journey and we wish him well as he steps away from his directorship."

CLINUVEL is undertaking a search process to appoint a new Director. The new Director will complement the current mix of skill, diversity and experience of the existing Board and will provide additional skills to support the next stage of the Company.

- End -

About CLINUVEL PHARMACEUTICALS LIMITED

CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders. As pioneers in understanding the interaction of light and human biology, CLINUVEL's research and development has led to innovative treatments for patient populations with a clinical need for photoprotection and repigmentation. These patient groups range in size from 5,000 to 45 million worldwide. CLINUVEL's lead product, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). More information on EPP can be found at <http://www.epp.care>. Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Switzerland, the US and Singapore. For more information go to <http://www.clinuvel.com>.

SCENESSE® is a registered trademark of CLINUVEL PHARMACEUTICALS LTD.

Media enquiries

Lachlan Hay, CLINUVEL (UK) LTD. +44 1372 860 765 Lachlan.Hay@clinuvel.com

Investor enquiries

InvestorRelations@clinuvel.com

Forward-Looking Statements

This release to the Australian Securities Exchange and to press may contain forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause CLINUVEL's actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that the FDA may require additional studies beyond the studies planned for product candidates or may not provide regulatory clearances, including for SCENESSE®; that the FDA may not provide regulatory approval for any use of SCENESSE® or that the approval may be limited; that CLINUVEL may never file an NDA for SCENESSE® regulatory approval in the US; that the Company may not be able to access adequate capital to advance its vitiligo programs; that the Company may not be able to retain its current pharmaceutical and biotechnology key personnel and knowhow for further development of its product candidates or may not reach favourable agreements with potential pricing and reimbursement agencies in Europe and the US.

Level 6, 15 Queen Street T +61 3 9660 4900 www.clinuvel.com
Melbourne, Victoria 3000 F +61 3 9660 4999
Australia